Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Abbott Laboratories (ABT) has been a trending stock, though its shares returned +1.9% over the past month, underperforming the S&P 500's +5.1%. Despite this recent market underperformance, analysts project robust growth, with current quarter EPS expected to rise 9.7% to $1.25 and full-year revenue anticipated at $44.7 billion (+6.6%). The company's consistent earnings beats (3 of last 4 quarters) and a Zacks Rank #2 (Buy) suggest potential near-term market outperformance driven by favorable earnings estimate revisions, even as its valuation is assessed as at par with peers.

Analysis

Abbott Laboratories (ABT) presents a case of solid fundamental prospects contrasted with recent market underperformance. Over the past month, the stock's +1.9% return has lagged the S&P 500 composite's +5.1% gain. However, forward-looking indicators are robust, with consensus estimates pointing to double-digit earnings growth for both the current fiscal year (+10.5%) and the next (+10.0%). This is supported by healthy revenue growth projections, which are expected to accelerate from +6.6% in the current fiscal year to +7.6% in the next. While the company's recent execution has been mixed, with a slight revenue miss (-0.56%) in the last quarter and topping revenue estimates in only two of the last four quarters, it has consistently surpassed EPS estimates in three of those four periods. Despite a minor downward revision to the current quarter's consensus EPS (-0.4%), the overall positive trend in earnings estimates has earned the stock a Zacks Rank #2 (Buy). Valuation appears fair, with a 'C' grade indicating it trades at par with its peers, suggesting the positive outlook may be partially priced in.

Key Decisions for Investors

• Investors with a bullish outlook can focus on the strong, double-digit forward earnings projections and accelerating revenue growth as a basis for potential near-term outperformance, aligning with the Zacks #2 (Buy) rating.
• It is crucial to monitor the company's execution on top-line growth, as the recent history of revenue misses contrasts with a consistent ability to beat EPS estimates, indicating a potential risk if revenue targets are not met.
• Given that the stock's valuation is considered at par with peers and it has recently underperformed the broader market, investors should weigh whether the current price fully reflects the positive growth forecasts or if there is room for further appreciation.